The type 2 diabetes (T2D) drug market is expected to expand, fueled by a rich pipeline of agents. However, growth will be tempered because these emerging therapies will be predominantly later-to-market entrants of existing drug classes or combination treatments. Owing to the increased risk of cardiovascular (CV) and kidney disease associated with T2D, a high unmet need exists for affordable drugs that can safely and effectively manage this disease in the long term. The sodium-glucose co-transporter-2 (SGLT-2) inhibitors, such as AstraZeneca’s Farxiga / Forxiga, and glucagon-like peptide-1 (GLP-1) receptor agonists, such as Novo Nordisk’s Ozempic, are offering hope for greater CV and renal benefits. However, the physical and financial impacts of T2D continue to increase, highlighting the need for more-effective and more-affordable drug treatments.
- What are the treatment drivers and goals for type 2 diabetes?
- What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for type 2 diabetes?
- What are the prevailing areas of unmet need and opportunity in type 2 diabetes?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European endocrinologists for a hypothetical new type 2 diabetes drug?
Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 32 European endocrinologists fielded in March 2020
Key companies: AstraZeneca, Eli Lilly, Janssen, Merck, Novo Nordisk
Key drugs: Farxiga / Forxiga, Invokana, Januvia, Jardiance, Rybelsus, Trulicity, Victoza